Immunome Files FDA Application for Covid-19 Antibody Cocktail
By Matt Grossman
Immunome Inc. has submitted an investigational new drug
application to the Food and Drug Administration for a
three-antibody cocktail intended to treat Covid-19.
The cocktail, called IMM-BCP-01, has shown in lab studies that
it neutralizes the virus and reduces viral load in the lungs of
infected hamsters, Immunome said. In those studies the cocktail was
effective against Covid-19 variants, including the Delta
Outside of Immunome, scientists have begun researching whether
the newly discovered Omicron variant has become less susceptible to
existing antibody-based treatments.
When the FDA accepts the application, Immunome will work to
begin a study of IMM-BCP-01 in infected patients, the
Pennsylvania-based company said.
Write to Matt Grossman at firstname.lastname@example.org
(END) Dow Jones Newswires
November 29, 2021 07:31 ET (12:31 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.